贝达药业(300558) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥584,705,632.04, a decrease of 5.47% compared to ¥618,561,581.32 in the same period last year[3] - Net profit attributable to shareholders was ¥83,678,928.89, down 43.36% from ¥147,745,673.33 year-on-year[3] - The net cash flow from operating activities was ¥29,306,885.70, reflecting a significant decline of 62.21% compared to ¥77,551,312.52 in the previous year[3] - Basic earnings per share decreased to ¥0.20, down 44.44% from ¥0.36 in the same period last year[3] - Total operating revenue decreased to ¥584,705,632.04 from ¥618,561,581.32, representing a decline of approximately 5.5% year-over-year[21] - Net profit for the period was ¥79,272,651.53, down from ¥146,483,729.42, reflecting a decrease of approximately 46% year-over-year[22] - The company recorded a total comprehensive income of ¥52,598,102.57, down from ¥145,422,673.14, reflecting a decrease of about 64% year-over-year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,584,330,493.66, an increase of 4.99% from ¥6,271,432,076.94 at the end of the previous year[3] - The total current assets decreased from CNY 1,653,935,668.95 to CNY 1,521,527,534.15, a decline of approximately 8%[18] - The company's non-current assets increased from CNY 4,617,496,407.99 to CNY 5,062,802,959.51, representing an increase of about 9.6%[19] - The company's total liabilities increased from CNY 1,585,642,380.84 to CNY 1,792,191,334.80, reflecting an increase of about 13%[19] - The company's equity attributable to shareholders rose from CNY 4,560,887,934.57 to CNY 4,671,719,604.98, an increase of approximately 2.4%[20] Cash Flow - The company reported cash and cash equivalents of CNY 683,401,069.14, down from CNY 791,989,554.14, a decrease of about 13.7%[17] - Cash inflow from investment activities was ¥201,579,835.62, down from ¥522,454,394.17, indicating a decline of approximately 61% year-over-year[23] - The total cash inflow from financing activities was 438,021,887.80 CNY, while the cash outflow was 8,265,248.00 CNY, resulting in a net cash flow of 429,756,639.80 CNY[24] - The net increase in cash and cash equivalents was -108,588,485.00 CNY, compared to -515,163,728.92 CNY in the previous period[24] Operational Changes and Investments - The company raised ¥429,756,639.80 from financing activities, a dramatic increase of 21,899.68% compared to a cash outflow of ¥1,971,390.00 in the previous period[5] - The company made new investments in Wuhan Heyuan Biotechnology Co., Ltd. and Zhejiang Shimai Pharmaceutical Co., Ltd., leading to a 138.75% increase in other equity instrument investments to ¥802,919,674.87[5] - The company plans to temporarily use up to RMB 300 million of idle raised funds to supplement working capital, with a usage period not exceeding 12 months[14] - The company plans to invest CNY 30 million in Zhejiang Shimai Pharmaceutical Co., Ltd., acquiring a 1.3453% stake, and will also invest CNY 76 million to acquire an additional 3.4081% stake from Ningbo Kaiming Investment Management Partnership[16] Research and Development - The clinical trial application for BPI-371153, an innovative oral PD-L1 inhibitor, was approved in January 2022, indicating ongoing R&D efforts[12] - The company has successfully commercialized Beanting, which was approved for multiple cancer indications, including metastatic colorectal cancer and advanced NSCLC[12] - Research and development expenses were ¥107,640,306.79, down from ¥118,329,417.69, showing a reduction of about 9% year-over-year[21] Management and Governance - The company’s actual controller holds a total of 23.01% of the shares, ensuring stable governance and control[9] - The company appointed Mr. Cai Wanyu as Senior Vice President to manage the production center and Shengzhou industrial base, effective from January 21, 2022[15] - The company is focused on enhancing its business capabilities to ensure stable production and market promotion of its drugs amid market changes[11]